新诊断2型糖尿病患者的短期胰岛素强化治疗  

Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetic Mellitus Patients

作　　者：姬秋和[1] 白瑜[1] 

机构地区：[1]第四军医大学西京医院,陕西西安710032

出　　处：《医学与哲学（B）》2015年第4期11-14,68,共5页Medicine & Philosophy(B)

基　　金：陕西省科技统筹创新工程;项目编号:2013KTZB03-02

摘　　要：2型糖尿病在全球范围内具有患病率高、血糖控制效果差、并发症多等特点,在我国尤为突出。短期胰岛素强化治疗作为一种对新诊断2型糖尿病患者有效治疗手段不仅可以迅速解除糖毒性,获得长期血糖缓解,促进胰岛β细胞功能恢复,而且可以降低微血管及大血管事件发生率,延缓并发症的发生发展,改善患者预后。结合我国患者自身特点,中华医学会推荐,当新诊断2型糖尿病患者糖化血红蛋白(HbA1c)>9%,或者空腹血糖>11.1mmol/L时,可以在生活方式干预、体重管理基础上积极进行短期胰岛素强化治疗。In the world ,the characteristics of type 2 diabetes include high prevalence rate ,poor glucose control ,a great deal of complications and so on .These conditions are especially serious in China .Short‐term intensive insulin therapy as an effective treatment for newly diagnosed type 2 diabetes mellitus patients not only can rapidly relieve sugars toxicity , maintain long‐term glucose control ,restore and maintain the function of pancreatic beta‐cell ,but also reduce the morbidity of microvascular and major vascular events ,delay the development of complications and improve the prognosis of patients . Combined with Chinese conditions ,Chinese Medical Association recommended：when newly diagnosed patients＇HbA1c 〉9% or fasting glucose ≥11 .1 mmol/L ,patients can adopt the short‐term intensive insulin therapy ,with the foundation of lifestyle intervention ,and weight management treatment .

关 键 词：2型糖尿病 糖化血红蛋白 胰岛Β细胞 胰岛素强化治疗 

分 类 号：R587.1[医药卫生—内分泌]